Treace Medical Shares Interim Data From Corrective Toe Surgery Trial
Treace Medical Concepts Inc (NASDAQ: TMCI) announced an audio poster presentation of the latest interim analysis from the ALIGN3D clinical study following the Lapiplasty Procedure for surgical treatment of hallux valgus (bunions).
The data showed:
Early return to weight bearing in a walking boot at an average of 8.3 days.
A low recurrence rate, defined as loss of radiographic correction, was observed in 1.4% of patients (2 out of 144).
An 81% reduction in pain (Visual Analog Scale) was reported at 24 months post-procedure (n=107).
The interim analysis also continued to report statistically significant improvement in Patient-Reported Outcomes.
At 24 months post-surgery (n=107), an 82% and 84% improvement was observed in walking/standing and social interaction, respectively.
Further, statistically significant improvements in physical, mental, and social health scores were reported.
Price Action: TMCI shares closed 4.37% lower at $23.33 on Tuesday.
See more from Benzinga
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
Tencent Music Pushes Hong Kong Listing As Soon As Next Week: Report
'Can All Trump Interviews Be Like This?' Jimmy Kimmel Praises Indian News Channel For Constantly Fact-Ch
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.